Gut Microbiome Linked to Biliary Atresia Progression in Infants

A new review published in the World Journal of Pediatric Surgery reveals that the gut microbiome may be a critical driver of disease progression in biliary atresia (BA), the leading cause of liver transplantation in children. The study, led by Dr. Vandana Jain, synthesizes evidence showing that infants with BA harbor a severely imbalanced gut microbial ecosystem even before corrective surgery. Beneficial bacteria like Bifidobacterium are depleted, while harmful pathobionts such as Streptococcus and Enterococcus overgrow. These disturbances persist after the Kasai portoenterostomy and are linked to worse outcomes, including failure to clear jaundice and increased liver fibrosis. The review highlights the gut-liver axis as a key pathway, with microbial metabolites like butyrate showing potential protective effects. The findings suggest that the microbiome is not just a bystander but an active participant in BA.

Biliary atresia affects approximately one in 10,000 to 15,000 infants worldwide. The standard surgery, the Kasai procedure, restores bile drainage in only about 60% of cases, and most patients eventually require liver transplantation by early adulthood. The review notes that current post-surgical practices, such as routine use of broad-spectrum antibiotics and reduced breastfeeding, may further disrupt the developing microbiome. The consistent patterns of dysbiosis across multiple studies point to an urgent need for research into microbiome-modulating therapies. Early trials with probiotics like Lactobacillus rhamnosus GG have shown mixed results, indicating that strain selection and timing are critical.

This synthesis of evidence opens the door to new therapeutic approaches for BA, where treatment options have remained limited for decades. By integrating microbiome science into clinical care, researchers aim to improve native liver survival and reduce the need for transplantation. The review calls for re-evaluating clinical practices like prophylactic antibiotic use, which may inadvertently harm beneficial bacteria. Dr. Jain and colleagues emphasize that the microbiome is modifiable, offering hope for changing the disease trajectory in these vulnerable infants.